Becton, Dickinson and Company $BDX Shares Purchased by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 31.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,352 shares of the medical instruments supplier’s stock after buying an additional 7,241 shares during the period. UniSuper Management Pty Ltd’s holdings in Becton, Dickinson and Company were worth $5,681,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. SOA Wealth Advisors LLC. increased its holdings in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 95 shares during the last quarter. Bell Investment Advisors Inc boosted its holdings in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the third quarter valued at approximately $32,000. Bank of Jackson Hole Trust increased its stake in Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 95 shares during the last quarter. Finally, CVA Family Office LLC raised its holdings in Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 97 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $201.84 on Monday. The firm has a market cap of $57.51 billion, a P/E ratio of 34.62, a P/E/G ratio of 2.23 and a beta of 0.23. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The business’s 50-day moving average price is $197.40 and its 200 day moving average price is $190.53. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.89 billion during the quarter, compared to analysts’ expectations of $5.91 billion. During the same period last year, the firm earned $3.81 EPS. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were given a $1.05 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s payout ratio is 72.04%.

Wall Street Analyst Weigh In

BDX has been the topic of several research analyst reports. Jefferies Financial Group lifted their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Royal Bank Of Canada raised their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $207.64.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,605 shares of company stock worth $524,643 over the last three months. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.